Stock Market & Financial Investment News

Conatus Pharmaceuticals price target lowered to $14 from $16 at StifelStifel cut its price target on Conatus as the firm thinks the extension of P2b ACLF data timelines due to slower than expected enrollment is negative. However, the firm keeps a Buy rating on the stock.